Опубликована: Янв. 1, 2024
Язык: Английский
Modern Rheumatology Journal, Год журнала: 2024, Номер 18(2), С. 95 - 102
Опубликована: Апрель 22, 2024
Patients with juvenile-onset systemic lupus erythematosus (jSLE) account for up to 25% of all SLE patients. The main difference between jSLE and in adults is the greater role genetic factors pathogenesis, higher activity, earlier development complications need more aggressive immunosuppressive therapy, which allows us consider onset disease childhood as a special phenotype SLE. relevance study arises from variability clinical manifestations unpredictability course, difficulty early diagnosis, rapid organ damage unfavorable life prognosis. article presents most important modern data on classification, features picture treatment approaches practical point view.
Язык: Английский
Процитировано
1
Best Practice & Research Clinical Rheumatology, Год журнала: 2024, Номер unknown, С. 101962 - 101962
Опубликована: Июнь 1, 2024
Язык: Английский
Процитировано
1
Modern Rheumatology Journal, Год журнала: 2024, Номер 18(4), С. 99 - 105
Опубликована: Авг. 21, 2024
The treatment of juvenile-onset systemic lupus erythematosus (jSLE) is a complex task in view the diversity clinical manifestations and course disease as well high risk organ damage. need to create separate therapeutic principles for jSLE justified by greater intensification therapy due both doses used combination larger number different drugs patient. However, basis today mainly extrapolation data obtained studies with adult patients. review reflects modern ideas about spectrum jSLE, particular emphasis on efficacy, safety timing possible optimization options.
Язык: Английский
Процитировано
0
Cureus, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 13, 2024
Systemic lupus erythematosus (SLE) is an autoimmune disorder with a complex clinical course and diverse presentations. The immunopathogenesis of SLE has long intrigued physicians researchers. Despite its extensive global prevalence, there no specific treatment to prevent treat SLE, in the majority patients, management involves controlling disease remissions symptom reactivations or flares. patients suffer from damage different organs body, complicating management. They are predisposed infectious diseases that could contribute enhanced progression. Devising effective strategies requires comprehensive understanding effects influence on immune system. affects females more frequently than men. However, male often severe females. Gender variations have also been noted manifestations SLE. In light this, additional research needed understand these promote progress gender-specific patient strategies. This review aimed compare gender consequences, immunopathogenesis, associated consequences between female patients. An literature search was conducted collect relevant data. PubMed, MEDLINE, Embase, Google Scholar were searched inception present for articles compared outcomes disorders terms among We explored mechanisms underlying gender-based disease-related consequences. Additionally, we provide key updates regarding
Язык: Английский
Процитировано
0
Current Opinion in Rheumatology, Год журнала: 2024, Номер unknown
Опубликована: Дек. 11, 2024
Systemic lupus erythematosus (SLE) is a severe autoimmune/inflammatory disease. Patients with juvenile disease-onset and those of non-European ancestry are most severely affected. While the exact pathophysiology remains unknown, common rare gene variants in context environmental exposure epigenetic alterations involved. This manuscript summarizes current understanding genetic contributors to SLE risk, manifestations outcomes.
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0